Browse

A biotech startup recently faced a setback when a clinical trial did not achieve its primary goals. Rather than discarding the results, the company chose to analyze the data for new insights. The…

Edgewise Therapeutics announced on June 16, 2026 that it will advance its investigational therapy for a genetic heart disease into a registrational Phase 3 trial. The decision follows an updated a…